84-1169-13　［取扱停止］EGFR (Epidermal Growth Factor Receptor, Proto-oncogene c-ErbB-1, Receptor Tyrosine-protein Kinase erbB-1, ERBB1) 50ug　E3375-25R

特徴

• Epidermal growth factor (EGF) receptor is a 170kD tyrosine kinase.
• Ligand binding results in receptor dimerization, autophosphorylation, activation of downstream signaling and lysosomal degradation.
• Phosphorylation of Tyr845 in the kinase domain is implicated in stabilizing the activation loop, maintaining the enzyme in an active state and providing a binding surface for substrate proteins.
• c-Src is involved in phosphorylation of Tyr845.
• Phospho-tyrosine 992 is a direct binding site for the PLC gamma SH2 domain, resulting in activation of PLC gamma-mediated downstream signaling.
• Phosphorylation of Tyr1045 creates a major docking site for c-Cbl.
• Binding of c-Cbl to the activated EGFR leads to receptor ubiquitination and degradation.
• Phospho-Tyr1068 of activated EGFR is a direct binding site for Grb2.
• Phospho-tyrosine 1148 and 1173 provide a docking site for SHC.
• Both sites are involved in the activation of MAP kinase signaling.
• Phosphorylation of EGFR on serine and threonine residues attenuates EGFR kinase activity.
• Serines 1046 and 1047 in the carboxy-terminal region of EGFR are sites phosphorylated by CaM kinase II.
• Mutations to either serine 1046 or 1047 upregulate tyrosine autokinase activity of EGFR.
• Applications:Suitable for use in Western Blot and Immunohistochemistry.
• Other applications not tested.
• Recommended Dilution:Western Blot: 1:500-1:1,000Immunohistochemistry: 1:50-1:100Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• Aliquots are stable for at least 12 months.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.